SGEN » Topics » [Signature page follows]

This excerpt taken from the SGEN 8-K filed Jun 1, 2007.

[Signature Page Follows]

 

-4-


The parties have executed this Agreement on the respective dates set forth below.

 

COMPANY:
SEATTLE GENETICS, INC.
By:  

/s/ Clay B. Siegall

 

Its:   President and CEO
Address:   21823 30th Drive SE
  Bothell, WA 98021
Date:  

5/23/07

 

EMPLOYEE:
Pamela A. Trail

/s/ Pamela A. Trail

Signature
Address:  
 
Date:  

5/22/07

 

This excerpt taken from the SGEN 10-Q filed May 8, 2007.

[Signature page follows]

 

-74-


IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date.

 

SEATTLE GENETICS, INC.
By:   /s/ Clay B. Siegall
Name:   Clay B. Siegall
Title:   President & CEO
AGENSYS, INC.
By:   /s/ Donald B. Rice
Name:   Donald B. Rice
Title:   Chairman, President & CEO
These excerpts taken from the SGEN 10-Q filed Aug 9, 2005.

[Signature page follows]

 

[***]     Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

13


IN WITNESS WHEREOF, the parties hereto have each caused this Agreement to be signed and delivered by its duly authorized officer or representative as of the date first set forth above.

 

SEATTLE GENETICS, INC.       ORGANICHEM CORPORATION
By:  

/s/ Clay B. Siegall

      By:   /s/ Eric W. Smart

Name:

 

Clay B. Siegall

     

Name:

  Eric W. Smart

Title:

 

President & CEO

     

Title:

  VP, Business Development

 

[***]     Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

14


[Signature page follows]

 

[***]     Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-25-


IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.

 

SEATTLE GENETICS, INC.

     

PROTEIN DESIGN LABS, INC.

By:

 

/s/ Clay B. Siegall

     

By:

 

/s/ Mark McDade

Name:

 

Clay B. Siegall

     

Name:

 

Mark McDade

Title:

 

President and Chief Executive Officer

     

Title:

 

Chief Executive Officer

 

[***]     Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-26-


[Signature page follows]

 

[***]     Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

33


IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date.

 

SEATTLE GENETICS, INC.
By:   /s/ Clay B. Siegall

Name:

  Clay B. Siegall

Title:

  President and CEO

 

MEDIMMUNE, INC.
By:   /s/ David M. Mott

Name:

  David M. Mott

Title:

  CEO

 

These excerpts taken from the SGEN 10-Q filed Aug 2, 2005.

[Signature page follows]

 


*** Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

-2-


IN WITNESS WHEREOF, the parties have caused this AMENDMENT NO. 3 to be executed by their respective duly authorized officers as of the THIRD AMENDMENT DATE.

 

SEATTLE GENETICS, INC.
By:  

/s/ Clay B. Siegall


    (Signature)
Name:   Clay B. Siegall, Ph.D.
Title:   President and Chief Executive Officer
ARIZONA SCIENCE & TECHNOLOGY ENTERPRISES
By:  

/s/ Peter Slate


    (Signature)
Name:   Peter Slate
Title:   Chief Executive Officer

(Signature page follows)

 


*** Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

- 2 -


IN WITNESS WHEREOF, the parties have caused this Amendment No. 2 to be executed by their respective duly authorized officers as of the Second Amendment Date.

 

SEATTLE GENETICS, INC.
By:  

/s/ Clay B. Siegall


    (Signature)
Name:   Clay B. Siegall, Ph.D.
Title:   President and Chief Executive Officer
GENENCOR INTERNATIONAL, INC.
By:  

/s/ Mark A. Goldsmith


    (Signature)
Name:   Mark A. Goldsmith, MD, Ph.D.
Title:   Senior Vice President, Health Care

 

- 3 -

[Signature page follows]

 

39


IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized officers as of the Effective Date.

 

APPLERA CORPORATION

through CELERA GENOMICS GROUP

  SEATTLE GENETICS, INC.
By:  

/s/ Kathy Ordoňez


  By:  

/s/ Clay B. Siegall


    (Signature)       (Signature)
   

Clay B. Siegall


(Printed Name) Kathy Ordoňez   (Printed Name)
   

President & CEO


(Title) Senior Vice President   (Title)

            July 20, 2004


 

July 20, 2004


Date   Date

 

40

This excerpt taken from the SGEN 10-Q filed Apr 18, 2005.

[Signature page follows]


[***] Confidential treatment has been requested with respect to the omitted portions.

 

Confidential

  -31-    


IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date.

 

SEATTLE GENETICS, INC.

By:

 

Clay B. Siegall


Name:

 

/s/ Clay B. Siegall


Title:

 

President & CEO


CURAGEN CORPORATION

By:

 

Jonathan M. Rothberg


Name:

 

/s/ Jonathan M. Rothberg


Title:

 

CEO



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki